All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Second Genome

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery

Contact the Supplier

Lead Product(s): Undisclosed

Therapeutic Area: Gastroenterology

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Gilead Sciences

Deal Size: $1,538.0 million Upfront Cash: $38.0 million

Deal Type: Collaboration April 06, 2020

Details:

Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines.